AKT1 and glioma: It has proved that endogenous AKT can be activated in TMZ-treated cells [9], overexpression of an active form of AKT increases glioma cell resistance to TMZ [6] and inhibition of AKT function is associated with increased cell sensitivity to TMZ [9].